Table 2.
Therapy any time during follow-up by IBD type and age groups
| Therapya | Age 18–64 years | Age ≥ 65 years | p Value |
|---|---|---|---|
| All patients | n = 54,971 | n = 8788 | |
| Corticosteroid | 49,592 (90.2) | 8410 (95.7) | < 0.0001 |
| Immunomodulator | 11,374 (20.7) | 960 (10.9) | < 0.0001 |
| Biologic | 10,326 (18.8) | 519 (5.9) | < 0.0001 |
| UC patients | n = 30,042 | n = 5395 | |
| Corticosteroid | 28,459 (94.7) | 5258 (97.5) | < 0.0001 |
| Immunomodulator | 5008 (16.7) | 489 (9.1) | < 0.0001 |
| Biologic | 3151 (10.5) | 196 (3.6) | < 0.0001 |
| CD patients | n = 24,929 | n = 3393 | |
| Corticosteroid | 21,133 (84.8) | 3152 (92.9) | < 0.0001 |
| Immunomodulator | 6366 (25.5) | 471 (13.9) | < 0.0001 |
| Biologic | 7175 (28.8) | 323 (9.5) | < 0.0001 |
Data are expressed as n (%)
CD Crohn’s disease, IBD inflammatory bowel disease, UC ulcerative colitis
a Table represents cumulative drug use during follow-up, therefore each row is not mutually exclusive